Physician profile
Michael R Marvin
NPI 1265455406
$143,409.35
in general payments reported to CMS, 2019-2025
9 companies · $37K in 2025
The $37K reported for 2025 was more than what 97% of Transplant Surgery providers received nationally (typical 2025 total: $423).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45K · 2020: $5,584 · 2021: $10K · 2022: $16K · 2023: $18K · 2024: $11K · 2025: $37K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $54K · Travel and Lodging: $5,663 · Consulting Fee: $5,174 · Food and Beverage: $1,159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $54,029.00 |
| Travel and Lodging | $5,662.89 |
| Consulting Fee | $5,174.00 |
| Food and Beverage | $1,158.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $76,518.68 | 2021-2025 | |
| Veloxis Pharmaceuticals, INC. | $32,107.20 | 2019-2023 | Envarsus |
| E.R. Squibb & Sons, L.L.C. | $22,908.21 | 2019-2020 | |
| Genzyme Corporation | $11,446.13 | 2019-2024 | |
| Boston Scientific Corporation | $150.00 | 2021 | |
| Covidien Lp | $101.73 | 2019 | |
| Medtronic, INC. | $80.17 | 2024 | Ligasure |
| Ethicon US, LLC | $68.86 | 2020 | |
| Kamada Ltd. | $28.37 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Marvin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.